These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27225358)

  • 21. Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings.
    Mikkelsen AP; Hansen ML; Olesen JB; Hvidtfeldt MW; Karasoy D; Husted S; Johnsen SP; Brandes A; Gislason G; Torp-Pedersen C; Lamberts M
    Europace; 2016 Apr; 18(4):492-500. PubMed ID: 26443443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 23. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    Lip GY
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():35-44. PubMed ID: 22518392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
    Gage BF; Cardinalli AB; Albers GW; Owens DK
    JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
    Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex.
    Pilcher SM; Alamneh EA; Chalmers L; Bereznicki LR
    Ann Pharmacother; 2020 Sep; 54(9):837-845. PubMed ID: 32019321
    [No Abstract]   [Full Text] [Related]  

  • 27. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study.
    Lefebvre MC; St-Onge M; Glazer-Cavanagh M; Bell L; Kha Nguyen JN; Viet-Quoc Nguyen P; Tannenbaum C
    Can J Cardiol; 2016 Feb; 32(2):169-76. PubMed ID: 26277091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
    Hussein A; Saliba W; Wazni OM
    Cleve Clin J Med; 2015 Dec; 82(12 Suppl 2):S11-6. PubMed ID: 26694887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.
    Bajorek B; Magin PJ; Hilmer S; Krass I
    J Clin Pharm Ther; 2016 Aug; 41(4):432-40. PubMed ID: 27338004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
    Angoulvant D; Villejoubert O; Bejan-Angoulvant T; Ivanes F; Saint Etienne C; Lip GYH; Fauchier L
    Chest; 2015 Aug; 148(2):491-498. PubMed ID: 25812113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the Appropriateness of Oral Anticoagulation for Atrial Fibrillation in Advanced Frailty: Use of Stroke and Bleeding Risk-Prediction Models.
    O'Caoimh R; Igras E; Ramesh A; Power B; O'Connor K; Liston R
    J Frailty Aging; 2017; 6(1):46-52. PubMed ID: 28244558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Banerjee A; Clementy N; Haguenoer K; Fauchier L; Lip GY
    Am J Med; 2014 Oct; 127(10):972-8. PubMed ID: 24929021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
    Gomberg-Maitland M; Wenger NK; Feyzi J; Lengyel M; Volgman AS; Petersen P; Frison L; Halperin JL
    Eur Heart J; 2006 Aug; 27(16):1947-53. PubMed ID: 16774980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
    Pandya E; Bajorek BV
    J Clin Pharm Ther; 2016 Dec; 41(6):667-676. PubMed ID: 27704588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
    O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
    Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.